Standard Therapies for Pulmonary Arterial Hypertension

Clinics in Chest Medicine

Volumn 28, Issue 1, 2007, Pages 91-115

  Alam, Shoaib ^a   Palevsky, Harold I ^b,c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGITOXIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; HEPARIN; ITRACONAZOLE; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; METOLAZONE; NIFEDIPINE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SITAXSENTAN; SPIRONOLACTONE; UNINDEXED DRUG; WARFARIN;

ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD VESSEL REACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ELECTROLYTE DISTURBANCE; HEART FAILURE; HEART RATE; HUMAN; HYPOXEMIA; INDUCED HYPOTENSION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MEDICAL DECISION MAKING; NONHUMAN; OXYGEN THERAPY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; STANDARD; SURVIVAL RATE; TACHYCARDIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; COMORBIDITY; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; OXYGEN INHALATION THERAPY; SLEEP APNEA, OBSTRUCTIVE; SPIRONOLACTONE;

EID: 33847413082     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.12.003     Document Type: Review

References (132)

1. Romberg E. Über sklerose der lungen arterie. Dtsch Arch Klin Med 48 (1891) 197-206 [in German]
2. Dresdale D.T., Schultz M., and Michtom R.J. Primary pulmonary hypertension. I: clinical and hemodynamic study. Am J Med 11 6 (1951) 686-705
3. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 2 (1987) 216-223
4. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 112 7 (1990) 485-491
5. Barst R.J., Rubin L.J., McGoon M.D., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 6 (1994) 409-415
6. Barst R., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 334 5 (1996) 296-302
7. Rich S., and McLaughlin V.V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 34 4 (1999) 1184-1187
8. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 132 6 (2000) 425-434
9. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342 25 (2000) 1866-1870
10. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 9288 (2001) 1119-1123
11. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002) 896-903
12. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 6 (2002) 800-804
13. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 4 (2002) 780-788
14. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 12 (2002) 1477-1482
15. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 7 (2002) 515-522
16. Sitbon O., Gressin V., Speich R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 11 (2004) 1212-1217
17. Mikhail G.W., Prasad S.K., Li W., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 25 5 (2004) 431-436
18. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171 11 (2005) 1292-1297
19. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 2 (2005) 244-249
20. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 20 (2005) 2148-2157
21. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 10 (2006) 2049-2056
22. Naeije R., and Vachiery J.L. Medical therapy of pulmonary hypertension: conventional therapies. Clin Chest Med 22 3 (2001) 517-527
23. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114 3 (1998) 787-792
24. Wagenvoort C.A. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 77 5 (1980) 614-625
25. Bjornsson J., and Edwards W.D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60 1 (1985) 16-25
26. Pietra G.G., Edwards W.D., Kay J.M., et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80 5 (1989) 1198-1206
27. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 4 (1984) 580-587
28. Kawut S.M., Horn E.M., Berekashvili K.K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 95 2 (2005) 199-203
29. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 2 (1992) 76-81
30. Johnson S.R., Granton J.T., and Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 130 2 (2006) 545-552
31. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 9 (2001) 1682-1687
32. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 23 (2005) 3105-3111
33. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 9 (1999) 1197-1208
34. Rich S., and Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76 1 (1987) 135-141
35. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 35S-62S
36. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25 24 (2004) 2243-2278
37. British Cardiac Society Guidelines and Medical Practice Committee, Gibbs JS, Higenbottam TW. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86 Suppl 1 (2001) 11-13
38. Weissmann N., Hassell K.L., Badesch D.B., et al. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)?. Am J Physiol Lung Cell Mol Physiol 279 4 (2000) L683-L690
39. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93 3 (1980) 391-398
40. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet 1 8222 (1981) 681-686
41. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. Global initiative for chronic obstructive pulmonary lung disease (2005), National Heart, Lung and Blood Institute, Bethesda (MD). Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989 . Accessed January 25, 2007
42. Owens G.R., Rogers R.M., Pennock B.E., et al. The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease. N Engl J Med 310 19 (1984) 1218-1221
43. Kelley M.A., Panettieri Jr. R.A., and Krupinski A.V. Resting single-breath diffusing capacity as a screening test for exercise-induced hypoxemia. Am J Med 80 5 (1986) 807-812
44. Bowyer J.J., Busst C.M., Denison D.M., et al. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 55 4 (1986) 385-390
45. Widlitz A., and Barst R.J. Pulmonary arterial hypertension in children. Eur Respir J 21 1 (2003) 155-176
46. Douglas N.J., White D.P., Pickett C.K., et al. Respiration during sleep in normal man. Thorax 37 11 (1982) 840-844
47. Koo K.W., Sax D.S., and Snider G.L. Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 58 5 (1975) 663-670
48. Atwood Jr. C.W., McCrory D., Garcia J.G., et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126 1 Suppl (2004) 72S-77S
49. Podszus T., Bauer W., Mayer J., et al. Sleep apnea and pulmonary hypertension. Klin Wochenschr 64 3 (1986) 131-134
50. Weitzenblum E., Krieger J., Apprill M., et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 138 2 (1988) 345-349
51. Krieger J., Sforza E., Apprill M., et al. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest 96 4 (1989) 729-737
52. Apprill M., Weitzenblum E., Krieger J., et al. Frequency and mechanism of daytime pulmonary hypertension in patients with obstructive sleep apnoea syndrome. Cor Vasa 33 1 (1991) 42-49
53. Laks L., Lehrhaft B., Grunstein R., et al. Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J 8 4 (1995) 537-541
54. Chaouat A., Weitzenblum E., Krieger J., et al. Pulmonary hemodynamics in the obstructive sleep apnea syndrome: results in 220 consecutive patients. Chest 109 2 (1996) 380-386
55. Sajkov D., Wang T., Saunders N., et al. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am J Respir Crit Care Med 159 5 Pt 1 (1999) 1518-1526
56. Sanner B.M., Doberauer C., Konermann M., et al. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 157 21 (1997) 2483-2487
57. Niijima M., Kimura H., Edo H., et al. Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 159 6 (1999) 1766-1772
58. Bady E., Achkar A., Pascal S., et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 55 11 (2000) 934-939
59. Alchanatis M., Tourkohoriti G., Kakouros S., et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 68 6 (2001) 566-572
60. Yamakawa H., Shiomi T., Sasanabe R., et al. Pulmonary hypertension in patients with severe obstructive sleep apnea. Psychiatry Clin Neurosci 56 3 (2002) 311-312
61. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group. N Engl J Med 335 9 (1996) 609-616
62. Sajkov D., Wang T., Saunders N.A., et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165 2 (2002) 152-158
63. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure. A randomized, controlled cross-over study. Eur Heart J 27 9 (2006) 1106-1113
64. Kessler R., Chaouat A., Schinkewitch P., et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 120 2 (2001) 369-376
65. Masa J.F., Celli B.R., Riesco J.A., et al. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest 119 4 (2001) 1102-1107
66. Sugerman H.J., Baron P.L., Fairman R.P., et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 207 5 (1988) 604-613
67. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 10 (1999) 709-717
68. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 6 (2005) e1-e82
69. Quinn D.A., Du H.K., Thompson B.T., et al. Amiloride analogs inhibit chronic hypoxic pulmonary hypertension. Am J Respir Crit Care Med 157 4 Pt 1 (1998) 1263-1268
70. Krayenbuehl H.P., Turina J., and Hess O. Left ventricular function in chronic pulmonary hypertension. Am J Cardiol 41 7 (1978) 1150-1158
71. Dittrich H.C., Chow L.C., and Nicod P.H. Early improvement in left ventricular diastolic function after relief of chronic right ventricular pressure overload. Circulation 80 4 (1989) 823-830
72. Gan C.T., Lankhaar J.W., Marcus J.T., et al. Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 290 4 (2006) H1528-H1533
73. Akera T., Baskin S.I., Tobin T., et al. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K +)- activated ATPase. Naunyn Schmiedebergs Arch Pharmacol 277 2 (1973) 151-162
74. Mathur P.N., Powles P., Pugsley S.O., et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction: a controlled clinical trial. Ann Intern Med 95 3 (1981) 283-288
75. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 8 (1997) 525-533
76. Jelliffe R.W., and Brooker G. A nomogram for digoxin therapy. Am J Med 57 1 (1974) 63-68
77. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 7 (2003) 871-878
78. Fogelman A.M., La Mont J.T., Finkelstein S., et al. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients. Lancet 2 7727 (1971) 727-729
79. Ingelfinger J.A., and Goldman P. The serum digitalis concentration: does it diagnose digitalis toxicity?. N Engl J Med 294 16 (1976) 867-870
80. Leor J., Goldbourt U., Rabinowitz B., et al. Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. The SPRINT Study Group. Cardiovasc Drugs Ther 9 5 (1995) 723-729
81. Eichhorn E.J., and Gheorghiade M. Digoxin. Prog Cardiovasc Dis 44 4 (2002) 251-266
82. Hager W.D., Fenster P., Mayersohn M., et al. Digoxin-quinidine interaction pharmacokinetic evaluation. N Engl J Med 300 22 (1979) 1238-1241
83. Bizjak E.D., and Mauro V.F. Digoxin-macrolide drug interaction. Ann Pharmacother 31 9 (1997) 1077-1079
84. Juurlink D.N., Mamdani M., Kopp A., et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289 13 (2003) 1652-1658
85. Archer S.L., Djaballah K., Humbert M., et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 158 4 (1998) 1061-1067
86. Lopes A.A., Maeda N.Y., Almeida A., et al. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 44 9 (1993) 701-706
87. Herve P., Launay J.M., Scrobohaci M.L., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99 3 (1995) 249-254
88. Kereveur A., Callebert J., Humbert M., et al. High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 20 10 (2000) 2233-2239
89. Cacoub P., Karmochkine M., Dorent R., et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 101 2 (1996) 160-164
90. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 4 (1995) 214-221
91. Collados M.T., Sandoval J., Lopez S., et al. Characterization of von Willebrand factor in primary pulmonary hypertension. Heart Vessels 14 5 (1999) 246-252
92. Hoeper M.M., Sosada M., and Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 12 6 (1998) 1446-1449
93. Wolf M., Boyer-Neumann C., Parent F., et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15 2 (2000) 395-399
94. Sakamaki F., Kyotani S., Nagaya N., et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 102 22 (2000) 2720-2725
95. Boyer-Neumann C, Brenot F, Wolf M, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995;73(4):735-6.
96. Veyradier A., Nishikubo T., Humbert M., et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 102 20 (2000) 2460-2462
97. Friedman R., Mears J.G., and Barst R.J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 96 9 (1997) 2782-2784
98. Girgis R.E., Champion H.C., Diette G.B., et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 172 3 (2005) 352-357
99. Welsh C.H., Hassell K.L., Badesch D.B., et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110 3 (1996) 710-717
100. Loyd J.E., Atkinson J.B., Pietra G.G., et al. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 138 4 (1988) 952-957
101. Frank H., Mlczoch J., Huber K., et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112 3 (1997) 714-721
102. Roman A., Rodes-Cabau J., Lara B., et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. Med Clin (Barc) 118 20 (2002) 761-766
103. Storstein O., Efskind L., Muller C., et al. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 179 2 (1966) 197-212
104. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 Suppl (2004) 204S-233S
105. Hales C.A., Kradin R.L., Brandstetter R.D., et al. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 128 4 (1983) 747-751
106. Hassoun P.M., Thompson B.T., and Hales C.A. Partial reversal of hypoxic pulmonary hypertension by heparin. Am Rev Respir Dis 145 1 (1992) 193-196
107. Yu L., Quinn D.A., Garg H.G., et al. Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 345 4 (2006) 1565-1572 [Epub 2006]
108. Hassoun P.M., Thompson B.T., Steigman D., et al. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am Rev Respir Dis 139 3 (1989) 763-768
109. Garg H.G., Hales C.A., Yu L., et al. Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative. Carbohydr Res 341 15 (2006) 2607-2612
110. Levine M.N., et al. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 Suppl (2004) 287S-310S
111. Robbins I.M., et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J 27 3 (2006) 578-584
112. Rubin L.J. Pulmonary arterial hypertension. Proc Am Thorac Soc 3 1 (2006) 111-115
113. Geerts W.H., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 3 Suppl (2004) 338S-400S
114. Dresdale D.T., Michtom R.J., and Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 30 3 (1954) 195-207
115. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 2 (1992) 70-75
116. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 6 (1999) 1925-1932
117. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 6 (1991) 464-469
118. Olivari M.T., Levine T.B., Weir E.K., et al. Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension. Chest 86 1 (1984) 14-19
119. Higenbottam T., Wheeldon D., Wells F., et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1 8385 (1984) 1046-1047
120. Groves B., Badesch D.B., Turkevich D., et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension and efficacy of treatment with calcium channel blockers and survival. In: Weir K. (Ed). Ion flux in pulmonary vascular control (1993), Plenum Press, New York 317-330
121. Sitbon O., Brenot F., Denjean A., et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151 2 Pt 1 (1995) 384-389
122. Sitbon O., Humbert M., Jagot J.L., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12 2 (1998) 265-270
123. Pepke-Zaba J.H., Dinh-Xuan A.T., Stone D., et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338 8776 (1991) 1173-1174
124. Ricciardi M.J., Knight B.P., Martinez F.J., et al. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 32 4 (1998) 1068-1073
125. Schrader B.J., Inbar S., Kaufmann L., et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 19 5 (1992) 1060-1064
126. Opitz C.F., Wensel R., Bettmann M., et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 24 4 (2003) 356-365
127. Ogata M., Ohe M., Shirato K., et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 57 1 (1993) 63-69
128. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 9 (2006) 1023-1030
129. Ziesche R., Petkov V., Wittmann K., et al. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 83 4 (2000) 406-409
130. Preston I.R., Klinger J.R., Houtchens J., et al. Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. Chest 121 2 (2002) 656-659
131. Zakliczynski M., Zebik T., Maruszewski M., et al. Usefulness of pulmonary hypertension reversibility test with sodium nitroprusside in stratification of early death risk after orthotopic heart transplantation. Transplant Proc 37 2 (2005) 1346-1348
132. Palmer S.M., Robinson L.J., Wang A., et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 113 1 (1998) 237-240